Anifrolumab denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for anifrolumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Anifrolumab as Experimental or Investigational

Anifrolumab (Saphnelo) received FDA approval for moderate-to-severe systemic lupus erythematosus (SLE) in adults on standard therapy. Despite this approval, Cigna may issue an experimental denial if its internal coverage policy has not been updated to align with the FDA approval, if the specific use falls outside the approved indication (for example, lupus nephritis or a pediatric population), or if Cigna applies a more restrictive evidence standard than FDA approval alone.

Because anifrolumab has FDA approval for its primary SLE indication, an experimental denial for an on-label use is highly vulnerable on appeal. The IRO external review stage in particular applies an independent evidence standard that typically recognizes FDA-approved indications as established, not investigational.

## Federal Appeal Rights

• Internal appeal: File within 180 days of the denial. Include the FDA approval documentation and any published guideline organization statements.
• External review (ACA §2719): Experimental/investigational denials are explicitly eligible for IRO review, which is binding on Cigna. File within approximately 4 months of the final internal denial. IROs routinely reverse experimental denials for FDA-approved drugs used in their approved indication.
• Expedited review: Available when delay poses a serious risk to health; 72-hour decision window.
• ERISA §503: Employer-plan members have full-and-fair review rights including access to Cigna's evidence-review criteria and any clinical guidelines applied.

## Documents to Gather

1. FDA approval documentation — the FDA prescribing label (package insert) for anifrolumab, confirming the approved indication and that the patient's use falls within it; download from the FDA's DailyMed or the manufacturer's labeling resource. 2. Diagnosis confirmation — rheumatology notes documenting the SLE diagnosis, disease activity, and clinical classification consistent with the FDA-approved indication. 3. Prior treatment history with dates and outcomes — documentation of standard-of-care therapies already in use and the clinical basis for adding anifrolumab, consistent with the approved indication requirements in the prescribing label. 4. Prescriber medical-necessity letter — a detailed letter from the treating rheumatologist confirming the on-label use, explaining the clinical rationale, and referencing applicable guideline organization support (e.g., ACR guidelines for SLE management). 5. Applicable guideline organization statements — published guidance from the relevant rheumatology guideline body recognizing anifrolumab as an accepted treatment option for moderate-to-severe SLE. 6. Cigna's coverage policy — obtain the specific Cigna coverage determination and evidence criteria applied; note whether the policy reflects the current FDA-approved labeling and whether Cigna's effective date post-dates the FDA approval.

## Criteria-Mapping Structure

For each element of Cigna's experimental-status test, provide a direct documentary answer. Typical elements include: FDA approval status (provide the approval date and indication text), peer-reviewed evidence (identify relevant published literature), and professional society acceptance (cite the applicable guideline organization). If the use is on-label, this grid should be straightforward to complete.

## Practical Next Step

Confirm the Cigna coverage policy effective date against the FDA approval date for anifrolumab. If the policy predates the approval, that date gap is the clearest single argument for reversal — include it prominently at the top of your appeal letter.